Fig 2: Pharmacological chaperone reduces tau phosphorylation in 3xTg mice. a Representative Western blots of total soluble tau (HT7), and phosphorylated tau at residues Ser396 (PHF13), Ser396/Ser404 (PHF1), Ser202/Thr205 (AT8), Thr231/Ser235 (AT180), and Thr181 (AT270) in brain cortex homogenates from 3xTg mice treated with TPT (3xTg/TPT) or control (3xTg). b Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values represent mean ± standard error of the mean (*p < 0.05, n = 3). c Representative immuno-histochemical staining images for PHF13, PHF1, AT8, AT180 and AT270 positive areas in brain hippocampus sections of 3xTg mice treated with TPT or control (scale bar: 100 µm). d Quantification of the integrated optical density (IOD) for the immunoreactivity to the same antibody shown in panel C. Values represent mean ± standard error of the mean (*p < 0.05, n = 4). e Representative western blots of GSK3a, GSK3ß, p-GSK-3a, p-GSK-3ß, cdk5, p35, p25, and PP2A in brain cortex homogenates from 3xTg mice treated with TPT or control (Ctrl) (n = 4 per group)